Literature DB >> 12971810

Prevalence of antidepressant-associated erectile dysfunction.

Raymond C Rosen1, Humberto Marin.   

Abstract

Sexual dysfunction in general and erectile dysfunction in particular are common problems in the overall population but also frequent symptoms of both untreated and treated depression. Erectile dysfunction and associated sexual dysfunction secondary to antidepressant therapy may occur in up to 90% of men with antidepressant-emergent sexual side effects; accurate assessment of prevalence rates depends on taking a detailed history regarding erectile dysfunction and other aspects of sexual function prior to treatment. In this review, we examine the available data on prevalence of erectile dysfunction and related sexual dysfunction in untreated depression and secondary to antidepressant medications compared with healthy populations. Possible mechanisms involved in serotonin reuptake inhibitor (SRI)-associated erectile dysfunction are examined. The assessment of SRI-associated erectile dysfunction is presented to aid in the management of this important and prevalent side effect. Treatment of antidepressant-associated erectile dysfunction can greatly increase the likelihood that patients will continue the medication that effectively treats their depression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12971810

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  15 in total

1.  Is hyperlipidemia or its treatment associated with erectile dysfunction?: Results from the Boston Area Community Health (BACH) Survey.

Authors:  Susan A Hall; Varant Kupelian; Raymond C Rosen; Thomas G Travison; Carol L Link; Martin M Miner; Peter Ganz; John B McKinlay
Journal:  J Sex Med       Date:  2009-02-09       Impact factor: 3.802

Review 2.  Abnormalities of Reproductive Function in Male Obesity Before and After Bariatric Surgery-A Comprehensive Review.

Authors:  Alberto Rosenblatt; Joel Faintuch; Ivan Cecconello
Journal:  Obes Surg       Date:  2015-07       Impact factor: 4.129

Review 3.  Prolactinergic and dopaminergic mechanisms underlying sexual arousal and orgasm in humans.

Authors:  Tillmann H C Krüger; Uwe Hartmann; Manfred Schedlowski
Journal:  World J Urol       Date:  2005-05-12       Impact factor: 4.226

4.  Pharmacotherapy of sexual dysfunctions : current status.

Authors:  Ajith Avasthi; Parthasarathy Biswas
Journal:  Indian J Psychiatry       Date:  2004-07       Impact factor: 1.759

5.  Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study.

Authors:  Y S Shim; C-U Pae; K J Cho; S W Kim; J C Kim; J S Koh
Journal:  Int J Impot Res       Date:  2013-11-28       Impact factor: 2.896

6.  Relative contributions of modifiable risk factors to erectile dysfunction: results from the Boston Area Community Health (BACH) Survey.

Authors:  Varant Kupelian; Andre B Araujo; Gretchen R Chiu; Raymond C Rosen; John B McKinlay
Journal:  Prev Med       Date:  2009-11-24       Impact factor: 4.018

7.  Common prescription medication use and erectile dysfunction: results from the Boston Area Community Health (BACH) survey.

Authors:  Varant Kupelian; Susan A Hall; John B McKinlay
Journal:  BJU Int       Date:  2013-07-02       Impact factor: 5.588

Review 8.  Adverse effects of drug therapies on male and female sexual function.

Authors:  Th Stadler; M Bader; S Uckert; M Staehler; A Becker; C G Stief
Journal:  World J Urol       Date:  2006-12       Impact factor: 3.661

9.  Antihypertensive drugs and erectile dysfunction as seen in spontaneous reports, with focus on angiotensin II type 1 receptor blockers.

Authors:  Elisabet Ekman; Staffan Hägg; Anders Sundström; Viktoria Werkström
Journal:  Drug Healthc Patient Saf       Date:  2010-03-29

10.  Antidepressant effect of geranylgeranylacetone in a chronic mild stress model of depression and its possible mechanism.

Authors:  Jing-Mei Zhong; Shao-Yuan Wu; Jie Bai; Qiang Guo; Jian Tao; Hui Chen; Nai-Wei Zhao; Zhong Zhao; Hao Fu
Journal:  Exp Ther Med       Date:  2012-08-16       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.